257 related articles for article (PubMed ID: 25894433)
1. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
[TBL] [Abstract][Full Text] [Related]
4. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
[TBL] [Abstract][Full Text] [Related]
6. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
[TBL] [Abstract][Full Text] [Related]
7. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
[TBL] [Abstract][Full Text] [Related]
10. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
[TBL] [Abstract][Full Text] [Related]
11. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
[TBL] [Abstract][Full Text] [Related]
12. Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma.
Rössle M; Sigg M; Rüschoff JH; Wild PJ; Moch H; Weber A; Rechsteiner MP
Virchows Arch; 2013 Nov; 463(5):623-31. PubMed ID: 24085553
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Molecular Methods and BRAF Immunohistochemistry (VE1 Clone) for the Detection of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Meta-Analysis.
Parker KG; White MG; Cipriani NA
Head Neck Pathol; 2020 Dec; 14(4):1067-1079. PubMed ID: 32358715
[TBL] [Abstract][Full Text] [Related]
14. A testing algorithm for detection of the B-type Raf kinase V600E mutation in papillary thyroid carcinoma.
Kim YH; Choi SE; Yoon SO; Hong SW
Hum Pathol; 2014 Jul; 45(7):1483-8. PubMed ID: 24745617
[TBL] [Abstract][Full Text] [Related]
15. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
[TBL] [Abstract][Full Text] [Related]
17. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
[TBL] [Abstract][Full Text] [Related]
20. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
Straccia P; Brunelli C; Rossi ED; Lanza P; Martini M; Musarra T; Lombardi CP; Pontecorvi A; Fadda G
Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
